Edwards J G, Glen-Bott M
J Neurol Neurosurg Psychiatry. 1984 Sep;47(9):960-4. doi: 10.1136/jnnp.47.9.960.
Six cases of convulsive seizures occurring during treatment with viloxazine notified to the Committee on Safety of Medicines (CSM) and two other cases from Japan were reviewed. A critical study of the patient's histories suggests a possible causal connection between drug and seizures in only two of these cases. The occurrence of convulsions is not in keeping with the results of animal experiments and of clinical trials in which epileptic patients were included, both of which suggest that viloxazine does not have epileptogenic properties and may have anticonvulsant actions. A worldwide review of clinical trials in which unwanted effects have been recorded suggests that viloxazine, even if possessing convulsive properties like other anti-depressants, is probably less epileptogenic than conventional tricyclics and is not contraindicated in epileptic patients requiring antidepressant medication.
向药品安全委员会(CSM)通报的6例在使用维洛沙嗪治疗期间发生惊厥发作的病例以及来自日本的另外2例病例接受了审查。对患者病史的严格研究表明,在这些病例中只有2例药物与癫痫发作之间可能存在因果关系。惊厥的发生与动物实验结果以及包含癫痫患者的临床试验结果不符,这两者均表明维洛沙嗪不具有致癫痫特性,可能具有抗惊厥作用。一项对记录了不良反应的临床试验的全球审查表明,即使维洛沙嗪像其他抗抑郁药一样具有惊厥特性,它引发癫痫的可能性可能比传统三环类药物小,对于需要抗抑郁药物治疗的癫痫患者并非禁忌。